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Abstract 
Background: Kaposi’s Sarcoma is the most common sarcoma and second most prevalent cancer seen in Tanzania. 
Little is known about Kaposi’s sarcoma in our setting as there is paucity of recent published data regarding this condi-
tion. This study describes the clinicopathological pattern and treatment outcome of Kaposi’s sarcoma at Bugando 
Medical Centre, a tertiary care hospital in northwestern Tanzania.
Methods: This was a prospective study of histologically confirmed Kaposi’s sarcoma that was conducted at Bugando 
Medical Center between July 2004 and June 2014.
Results: A total of 248 patients (M:F = 1.4:1) representing 2.4 % of all malignancies during the study period were 
enrolled into the study. The median age at presentation was 36 years. Females were younger than males (p = 0.04). 
Out of 248 patients, 122 (49.2 %) were HIV positive. Of these, 46 (37.7 %) were males and 76 (62.3 %) females. AIDS-
related Kaposi’s sarcoma were younger than HIV negative Kaposi’s sarcoma patients (p = 0.011). Median duration of 
symptoms was 6 months. Kaposi’s sarcoma was the AIDS defining disease in 82 (67.2 %) patients while in the remain-
ing 40 (32.8 %) it was diagnosed between 1 and 14 months after the initial diagnosis of AIDS. The lower limb was most 
frequently involved site in 28.9 % of patient. Females had more disseminated lesions compared with more localized 
lesions in the males (p = 0.001). The treatment modalities in this study included chemotherapy, radiotherapy, surgery 
and highly active antiretroviral therapy. Overall 126 (53.4 %) patients had significant improvement in quality of life at 
the end of 1 year follow up. Treatment related complication and mortality rates were 25.8 and 24.2 % respectively. 
Poor ACTG stage, CD4+ count <200 cells/µl, associated co-morbid illness, disseminated disease and poor adherent 
to chemotherapy were the significant independent factors associated with deaths (p < 0.001). Patient’s follow-up was 
generally poor and data on long-term survivals were not available as more than two-thirds of patients were lost to 
follow up.
Conclusion: Kaposi’s sarcoma is the most common malignant vascular tumor and HIV/AIDS- related cancer in our 
region. There is an urgent need to develop health education programmes to enhance the understanding of this dis-
ease and how it spreads, particularly among the younger generation.
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Background
Kaposi’s sarcoma (KS) is a malignant neoplasm of the 
vascular endothelium that is multifocal in origin involv-
ing the skin and other organs [1]. It was first described 
in 1872 by Moritz Kaposi, a Hungarian dermatologist 
who described KS as a rare multifocal angioproliferative 
tumor involving blood and lymphatic vessels and it was 
thought to occur only in Eastern Europe and the Medi-
terranean [2, 3]. However, Kaposi’s sarcoma is now the 
most frequently reported malignant skin tumor in some 
areas of Africa and was endemic in Africa even before 
the advent of the human immunodeficiency virus (HIV) 
[4, 5]. Kaposisi’s sarcoma has become the most common 
neoplasm in AIDS patients since it was first reported 
among homosexual men in the United States at the 
beginning of the AIDS epidemic [6]. On the basis of clini-
cal and epidemiological features, four types of Kaposi’s 
sarcoma have been recognized: classic, endemic (Afri-
can), iatrogenic and epidemic (AIDS related). The course 
of Kaposi’s sarcoma ranges from indolent, with only 
skin manifestations to fulminant with extensive visceral 
involvement [7].
Kaposi’s sarcoma poses problems in a histologic diag-
nosis because of its broad morphologic spectrum and 
similarity to many benign vasoproliferative lesions (e.g. 
pyogenic granuloma, bacillary angiomatosis, and microv-
enular hemangioma) and tumors with a prominent spin-
dle cell component (e.g. spindle cell hemangioma, spindle 
cell angiosarcoma, and dermatofibrosarcoma protu-
berans) [8, 9]. The variability in the biologic behavior of 
Kaposi’s sarcoma among individuals in the same group 
remains enigmatic.
Since the emergence of human immunodeficiency virus 
(HIV) infection, there has been a steady increase in the 
prevalence of Kaposi’s sarcoma worldwide. In the past, 
the incidence of Kaposi’s sarcoma was over 20,000 times 
higher in patients with AIDS than in the general popula-
tion [10]. However, the discovery and widespread use of 
highly active antiretroviral therapy (HAART) in devel-
oped countries has led to a substantial decrease in the 
incidence of AIDS-related Kaposi’s sarcoma (AIDS-KS). 
In addition, patients on HAART present with less aggres-
sive disease which is associated with less morbidity and 
mortality [11]. The burden of HIV infection and AIDS 
is greatest in the developing world and neoplastic com-
plications are increasingly encountered [12]. Although 
Kaposi’s sarcoma was endemic in central and east Africa 
before the AIDS epidemic, AIDS- Kaposi’s sarcoma has 
become the most frequently diagnosed tumor in several 
African countries [13–15]. The incidence has been stead-
ily increasing partly because of limited access to antiret-
roviral drugs and other preventive or curative therapies 
for AIDS associated cancers [15].
Kaposi’s sarcoma affects all ages, but lymph node 
involvement is more frequent in children and adoles-
cents. The disease predominantly affects men (M:F of 
12:1–3:1) [16]. The lower limbs are reported to be the 
predominant site affected in Africans [13–16].
The pathogenesis of Kaposi’s sarcoma is largely obscure 
and has been a subject of debate. In 1994, Chang et  al. 
[17] discovered HHV-8, or the Kaposi’s sarcoma-asso-
ciated herpes virus, as the causative agent of acquired 
immunodeficiency syndrome associated Kaposi’s sar-
coma and it has subsequently been found in all epidemio-
logic forms. Subsequent studies have showed that in over 
95 % of Kaposi’s sarcoma, KSHV is present regardless of 
HIV status [16, 18, 19]. It has now been established that 
KSHV is the primary and necessary factor in the develop-
ment of Kaposi’s sarcoma [4, 16].
Although the incidence of AIDS-related Kaposi’s sar-
coma is reported to have fallen by more than 90 % in some 
populations with the introduction of highly active antiret-
roviral therapy (HAART) and safe sexual practices, the 
situation may be the reverse in most of Africa due not only 
to a more rapid rate of progression of HIV disease but also 
to the unavailability of HAART in most communities [20].
Kaposi’s sarcoma is the most common malignant vas-
cular tumor and second most prevalent cancer seen in 
Tanzania and is commonly associated with HIV/AIDS 
[21–23]. Most patients present late after prior traditional 
medical treatment. However, despite this observation, 
there is a paucity of information regarding this condition 
in Tanzania and particularly the study area. This is partly 
due to a lack of published local data regarding Kaposi’s 
sarcoma and lack of cancer registries in this region. This 
study was designed to describe our ten-year experience 
in the management of Kaposi’s sarcoma outlining the 
clinicopathological pattern and treatment outcome of 
Kaposi’s sarcoma at Bugando Medical Centre, a tertiary 
care hospital in northwestern Tanzania.
Methods
Study design and setting
Between July 2004 and June 2014, a prospective study of 
histologically confirmed cases of Kaposi’s sarcoma was 
conducted at Bugando Medical Center. Bugando Medical 
Center is a tertiary care and teaching hospital for the Cath-
olic University of Health and Allied Sciences-Bugando 
(CUHAS-Bugando) in the Lake and Western Zones of the 
United Republic of Tanzania. It has 1000 beds and serves 
as a referral center for tertiary specialist care for a catch-
ment population of approximately 13 million people.
Study population
The study included all histologically confirmed cases of 
Kaposi’s sarcoma seen at Bugando Medical Center during 
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the period of study. Patients who had no histological 
results and those who refused to test for HIV infection 
were excluded from the study. The sample size for the 
study was determined using the Kish and Lisle formula 
(1965) as follows: n = Z2 p (1 − p)/d2 where, Zα = value 
at a specified confidence level, p = approximate propor-
tion of the event in the population and d =  acceptable 
margin of error in estimating the true population propor-
tion. The proportion of patients with Kaposi’s sarcoma in 
Tanzania is not known and it was estimated at 50 %, and 
given 1.96 value of the 95 % confidence interval and 0.05 
an acceptable margin of error, the minimum sample size 
required for the study was: 
The minimum sample size required for the study there-
fore was 384 patients. However, in this study only 248 
patients were available for the final analysis. Patients 
were screened for inclusion criteria and those who met 
the inclusion criteria were offered explanations about the 
study and requested to consent before being enrolled into 
the study. The diagnosis of Kaposi’s sarcoma was made 
clinically and confirmed histologically. Patients were 
assessed at the time of diagnosis of Kaposi’s sarcoma. 
The weight, vital signs and Kaposi’s sarcoma symptoms 
including pain, limb swelling, ulceration and disfigure-
ment were recorded, and a physical examination was 
performed. The tumor (T) size was defined as the sum 
of the greatest diameters of each measurable tumor. All 
patients in this study were requested to test for HIV 
infection using Tanzania HIV Rapid Test Algorithm [24] 
and CD4+ count using FACS or FACSCALIBUR from 
BD Biosciences USA. A determination of CD4 count was 
only performed in HIV positive patients. In patients with 
AIDS-related Kaposi’s sarcoma, the Karnofsky score sta-
tus of the patients was recorded. The tumor was staged 
according to AIDS Clinical Trials Group (ACTG) classi-
fication using the tumor (T), immune system (I) and sys-
temic illness (S) [25]. Tumor was defined as T0 (localized 
disease) if the disease was confined to the skin and lymph 
nodes or oral involvement was confined to the hard pal-
ate, or T1 (disseminated disease) if there was pulmonary 
or gastrointestinal involvement, tumor associated edema 
or ulceration, or extensive oral involvement. Morphologi-
cally the lesions were classified as macular, nodular and 
ulcerative. I (Immune system status): I0 (good risk): CD4 
cell count >200 cells/µl; I1 (poor risk): CD4 cell count 
<200 cells/µl. S (Systemic illness status): S0 (good risk): 
no systemic illness present; S1 (poor risk): systemic ill-
ness present with one or more of the following: Presence 
n =
1.96× 1.96× 0.50(1− 0.50)
0.05× 0.05
= 384
of opportunistic infection or thrush; One or more of B 
symptoms e.g. fever or night sweats; Performance status 
score less than 70 (Karnofsky performance status score); 
Other HIV related illness present e.g. neurological dis-
ease or lymphoma.
In every patient, biopsied tissue from representative 
Kaposi’s sarcoma lesion was fixed in 10  % formalin and 
embedded in paraffin wax. Routine histological sections 
were prepared using standard staining methods with 
H and E. The histologic features of Kaposi’s sarcoma 
included spindle-shaped tumor cells surrounding hyper-
emic vascular slits, often accompanied by extravasated 
erythrocytes, hemosiderin, and fibrosis.
Serum urea and electrolytes, liver function test and 
complete blood count with differential and platelet 
count were done at the time of diagnosis of Kaposi’s 
sarcoma and before administration of chemotherapy. 
Chest radiographs, ECG, abdominal ultrasound, faecal 
occult blood and gastrointestinal endoscopic examina-
tion were performed in appropriate cases. All patients 
were treated according to Bugando Medical Centre pro-
tocol which recommends that patients with Kaposi’s sar-
coma are started with Anti-KS therapy. This consisted 
of six courses of three weekly cycles of either vincristine 
monotherapy or as a combination of vincristine, doxo-
rubicin and bleomycin. In addition to Anti- Kaposi’s sar-
coma chemotherapy, patients with AIDS-related Kaposi’s 
sarcoma should start on HAART irrespective of CD4+ 
count. Radiotherapy and surgical excision of localized 
lesions were performed in appropriate cases. Treatment 
complications and outcome were monitored. Data on 
each patient were entered into a questionnaire prepared 
for the study. The study variables included age of patients 
at diagnosis, sex, HIV status, associated co-morbid con-
ditions, duration of illness, clinical presentation, anatom-
ical sites, tumor stage (ACTG), CD4+ count, treatment 
offered, treatment related complications and mortality. 
Follow-up of patients was for 12 months with documen-
tation of outcome at the end of the observation period.
Statistical data analysis
The statistical analysis was performed using the Statisti-
cal Package for Social Sciences (SPSS) version 17.0 for 
Windows (SPSS, Chicago, Illinois, USA). The median 
(and IQR) and ranges were calculated for continuous 
variables, whereas proportions and frequency tables were 
used to summarize categorical variables. The Chi square 
(χ2) test was used to test for the significance of associa-
tion between the independent (predictor) and depend-
ent (outcome) variables in the categorical variables. 
Student t test was used to test for significance of asso-
ciations between the predictor and outcome variables 
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in the continuous variables. The level of significance was 
considered as P  <  0.05. Multivariate logistic regression 
analysis was used to determine predictor variables that 
predicted the outcome.
Ethical consideration
Ethical approval to conduct the study was obtained from 
the CUHAS-Bugando/BMC joint institutional ethic 
review committee before the commencement of the 
study. Informed consent was sought from each patient 
before being enrolled into the study.
Results
Patient’s characteristics
During the study period, a total of 10324 malignancies 
were registered at Bugando Medical Centre. Of these, 
258 (2.4  %) were histopathologically confirmed Kaposi’s 
sarcoma giving an average of 25 cases annually. Out of 
these, 10 patients were excluded from the study due to 
missing data. Thus, 248 patients were enrolled into the 
study. The age of patients at diagnosis ranged from 3 to 
76 years with a median of 36 years (IQR = 34–38 years). 
The modal age group was 31–40  years. There were 144 
(58.1  %) males and 104 (41.9  %) females with a male to 
female ratio of 1.4: 1. Females were younger than males 
(median age of 28 years vs. males 37; p =  0.04). Out of 
248 patients, 122 (49.2  %) were HIV positive. Of these, 
46 (37.7  %) were males and 76 (62.3  %) females. Their 
ages ranged from 5 to 54 years with a median of 28 years 
(IQR  =  26–32  years). AIDS-related Kaposi’s sarcoma 
were younger than HIV negative KS patients (median age 
of 26  years among AIDS-KS vs median age of 48  years 
among HIV seronegative KS) and this was statistically 
significant (p = 0.011). Co-morbid conditions were seen 
in 73 (29.4 %) patients including 28 (38.4 %) pulmonary 
tuberculosis, 18 (24.7  %) anorectal sepsis, 12 (16.4  %) 
oral candidiasis, 6 (8.2  %) hypertension, 5 (6.6  %) dia-
betes mellitus and 4 (5.5  %) peptic ulcers. Co-morbid 
conditions were more common in patients with AIDS-
related Kaposi’s sarcoma than in those without AIDS-KS 
(62/122  =  46.6 versus 11/126  =  8.7  %). This difference 
was statistically significant (p = 0.011).
Clinicopathological presentation
The duration of symptoms of Kaposi’s sarcoma ranged 
from 1 to 14  months with a median of 6  months 
(IQR  =  4–8  months). Symptoms of Kaposi’s sarcoma 
were present in 212 (85.5  %) patients. The most com-
mon symptoms were swelling of extremities 124 (58.5 %), 
pain in 98 (46.2 %) and cosmetic disabilities in 52 (25.5 %) 
patients. Thirty-six (14.5  %) patients had no symptoms 
of Kaposi’s sarcoma and the diagnosis was made during 
routine clinical evaluation of other diseases. Amongst the 
122 HIV patients, Kaposi’s sarcoma was the AIDS defin-
ing disease in 82 (67.2 %) patients while in the remaining 
40 (32.8  %) it was diagnosed between 1 and 15  months 
after the initial diagnosis of AIDS. Twenty-two patients 
had used HAART for 1–13 months at the time of diag-
nosis of AIDS-related Kaposi’s sarcoma. Most of HIV 
patients, 84 (68.9  %) had Karnofsky performance score 
≥70 at the time of diagnosis. A total of 387 anatomical 
sites were documented in 248 patients giving an average 
of 1.6 anatomical sites per patients. The majority patients, 
214 (86.3 %) had multiple lesions (disseminated disease) 
and only 34 (13.7  %) had isolated lesions (localized dis-
ease). AIDS-related Kaposi’s sarcoma patients were more 
likely to present with disseminated form of the disease as 
compared to HIV seronegative patients (67.7 vs 26.1  %, 
p  =  0.014). At the time of diagnosis females had more 
widespread and advanced AIDS- related Kaposi’s sar-
coma compared to males (45.9 vs 18.6 %, p = 0.003). Skin 
241 (62.3  %) was most primary organ affected followed 
by oral cavity in 54 (14.0  %). The lower limb was most 
frequently involved anatomical site in 28.9 % of patients 
(Table  1). Visceral lesions included 4 rectal, 6 intestinal 
and 2 gastric tumors and accounted for 3.1 % of patients. 
Lymph node involvement in patients with AIDS-KS 
commonly occurred in adults whereas in patients with-
out AIDS-related Kaposi’s sarcoma lymph node involve-
ment was exclusively a disease of children. A total of 148 
(69.8 %) patients were found to be anemic. Out of these, 
118 (79.7 %) had AIDS-KS and the remaining 30 (20.3 %) 
patients had KS without HIV/AIDS. Tumor size ranged 
from 2 to 64 cm with a median of 32 cm (IQR =  28 to 
34  cm). The histological type was mixed cellularity in 
162 (63.3  %) patients, monomorphic in 56 (22.6  %) 
patients and anaplastic in 30 (12.1  %) patients. Accord-
ing to AIDS Clinical Trials Group (ACTG) classification 
in 122 patients with AIDS-related Kaposi’s sarcoma, the 
stage at presentation was T1, I1, S1 in 56 (45.9  %); T1, 
I1, S0 in 32 (26.2 %); T0, I0, S1, in 10 (8.2 %) and T0, I0, 
S0 in 24 (19.6 %). Overall 92 (75.4 %) patients had poor 
Table 1 Anatomical site distribution (N = 387)
Anatomical site Frequency Percentages




Upper limb 45 11.6
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prognosis disease comprising of 62 (81.6 %) females and 
30 (65.2 %) males. However, there was no significant dif-
ference between CD4 counts in males and females (OR 
1.54, 95  % CI 0.29–2.74, p =  0.675). Females had more 
disseminated cutaneous lesions involving an increased 
number of lesions at multiple anatomical sites compared 
with more localized lesions in the males (OR 1.9, 95  % 
CI 1.1–8.3, p = 0.001). Out of the 122 HIV patients, 25 
(20.5  %) were on antiretroviral therapy at the time of 
diagnosis and their CD4+ count ranged from 156 to 812 
cells/µl. Overall, CD4+ count available in 104 patients 
ranged from 34 to 798 cells/µl with a median of 148 
(IQR  =  140–152 cells/µl). A total of seventy-four HIV 
patients (71.2 %) had CD4+ count below 200 cells/μl and 
the remaining 30 patients (28.8  %) had CD4+ count of 
≥200 cells/μ. Viral load among HIV positive patients was 
not determined in this study due to lack of facilities for 
this important work up.
Treatment modalities
The treatment modalities in this study included cyto-
toxic chemotherapy, radiotherapy, surgery and antiviral 
therapy (HAART) given either alone or in combination 
as shown in Table 2. Overall, 108 (43.5 %) patients were 
treated with both HAART and chemotherapy and 86 
(34.6 %) patients were treated with chemotherapy alone. 
Of the 182 patients who had chemotherapy given either 
alone or in combination with HAART, only 76 (41.8  %) 
had completed the six cycles and the remaining 106 
(58.2 %) patients did not complete their treatment cycles 
because of death in the course of treatment after two to 
five courses, treatment stopped because of severe side 
effects or were lost to follow up shortly after commence-
ment of treatment. In this study chemotherapy was given 
either as Vincristine monotherapy or as a combination 
of Vincristine, doxorubicin and Bleomycin. The median 
time to start chemotherapy after the diagnosis of KS was 
4 months (IQR =  2–6 months). Only 5 (2.0 %) patients 
received radiotherapy. Thirty-two HIV patients had only 
antiretroviral therapy. Excision of ulcerated lesion and 
limb amputation were performed in four (1.6 %) patients 
each respectively. The remaining 9 (3.8  %) patients had 
only supportive care because of poor Karnofsky perfor-
mance score.
Treatment outcome and follow up
A total of 66 treatment related complications were 
recorded in 64 patients giving a complication rate of 
25.8  %. Table  3 below shows treatment related compli-
cations. These complications related to chemotherapy 
delayed chemotherapy by 1–2 weeks in 38 patients. Over-
all 126 (53.4 %) patients had significant improvement in 
quality of life (Karnofsky performance score ≥70) at the 
end of 1  year follow up. Sixty patients died at the end 
of 1 year giving a mortality rate of 24.2 %. Using multi-
variate logistic regression analysis, poor ACTG stage 
(OR =  4.5, 95  % CI (2.3–8.6), p =  0.011), CD4+ count 
<200 cells/µl (OR =  3.9, 95  % CI (1.1–5.8), p =  0.000), 
associated co-morbid illness (OR  =  4.1, 95  % CI (2.2–
7.2), p =  0.032), disseminated disease (OR =  6.7, 95  % 
CI (2.1–8.9), p  =  0.001) and poor adherent to chemo-
therapy (OR = 7.3, 95 % CI (3.3–9.2), p = 0.021) were the 
significant independent factors associated with deaths. 
Patient’s follow-up ranged from 1 to 12  months. At the 
end of follow up period, out of the 188 survivors, only 62 
(33.0  %) were available for follow up and the remaining 
126 (67.0 %) were lost to follow up.
Discussion
In this review, Kaposi’s sarcoma accounted for 2.4 % of all 
registered malignancies during the period of study. This 
Table 2 Distribution of  patients according to  treatment 
modalities
Treatment modality Number of patients Percentages
Chemotherapy + ARV therapy 
(HAART)
108 43.5
Chemotherapy alone 86 34.6
ARV therapy alone 32 12.9
Radiotherapy alone 5 2.0
Excision of ulcerated lesions ± skin 
grafting/flap
4 1.6
Limb amputation 4 1.6
Supportive care only 9 3.6
Total 248 100
Table 3 Distribution of  patients according to  treatment 
related complications (N = 66)
Treatment related complications Frequency Percentages




 Digestive toxicity 16
 Peripheral neuropathy 13
 Hair loss 4
 Skin necrosis 1
 Others 2
Complications related to surgical treatment 12 18.2
 Surgical site infections 5
 Skin grafting failure 2
 Wound gaping/dehiscence 2
 Stump necrosis 2
 Phantom pain 1
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figure is higher than the figure of 1.4 % reported by Man-
dong et al. [16] in Nigeria, but low compared to reports 
from central, east and southern Africa which was put at 
1.5–12 % of all cancers [4, 5, 13, 14, 18–21]. In a previous 
study at the same centre by Chalya et  al. [26], Kaposi’s 
sarcoma ranked second after malignant melanoma and 
accounted for 10.4 % of all skin cancers. This difference 
in the rate of Kaposi’s sarcoma reflects differences in the 
risk factors for Kaposi’s sarcoma from one country to 
another.
In the present study, AIDS-related Kaposi’s sarcoma 
was reported in 49.2 % of cases, a figure which is higher 
than 17–32 % reported from Central and Southern Afri-
can countries [13–16]. AIDS-related Kaposi’s sarcoma 
has also been reported to be highly prevalent in Mozam-
bique, a country that has one of the highest prevalence 
of HIV in the world [27]. In Western countries, the inci-
dence of AIDS-related Kaposi’s sarcoma has dropped 
from about 15 % at the beginning of the AIDS outbreak 
to 0.3 % [28]. The high incidence of HHV-8 infection and 
limited access to HAART and other preventive meas-
ures explain in part the reason for increasing incidence 
of AIDS-related Kaposi’s sarcoma in sub-Saharan Africa 
[29].
In this study, Kaposi’s sarcoma was more prevalent 
in males than in females, with a male to female ratio of 
1.4:1. This male predominance is in agreement with other 
many studies [15, 16]. However, in the current study 
AIDS related Kaposi’s sarcoma was predominantly a dis-
ease of females which is in keeping with others studies 
[30, 31]. The female predominance among AIDS-related 
Kaposi’s sarcoma in these studies may be attributed to 
the fact that the HIV epidemic is affecting an increasingly 
higher number of women in sub-Saharan Africa with 
over 60 % of persons living with the virus in this region 
being women. In addition, women are more frequently 
subjected to HIV testing as routine counseling and test-
ing has been applied to perinatal settings, and this may 
have allowed for a greater number of AIDS-related Kapo-
si’s sarcoma cases to be identified among women [30, 31].
In keeping with the findings in other studies [15, 20, 
32–36], females in this study reported to health facili-
ties at a significantly younger age than males. This could 
indicate that females were infected with HIV at an earlier 
age or that immunosuppression from HIV infection and 
Kaposi’s sarcoma pathogenesis progresses more rapidly 
in females.
The finding that AIDS-related Kaposi’s sarcoma occurs 
at an earlier age when compared with patients without 
AIDS-related Kaposi’s sarcoma has been reported previ-
ously [1, 37, 38]. This is in keeping with our study where 
AIDS-related Kaposi’s sarcoma were found to be younger 
than those without AIDS-related Kaposi’s sarcoma This 
may be explained by the fact that HIV is reported to be 
most prevalent among those aged 20–40  years in sub-
Saharan Africa, coupled with high-risk behavior and 
immunosuppression in this age group [1, 38].
Co-existing opportunistic infections, mainly TB, were 
a common feature in the recruited patients, with AIDS-
related Kaposi’s sarcoma patients bearing a higher burden 
than patients without AIDS-related Kaposi’s sarcoma. 
Similar observation has been reported by other authors 
[12, 15, 20, 21]. This observation may be explained by 
the fact that the degree of immunosuppression is usually 
higher in patients with AIDS-related Kaposi’s sarcoma 
than in those without AIDS-related Kaposi’s sarcoma. 
HIV contributes to the pathogenesis of Kaposi’s sar-
coma by inducing the immunosuppression necessary for 
the clinical expression of opportunistic disease. In addi-
tion, the HIV tat protein induces a number of cytokines 
known to promote HIV replication, while also inducing 
Kaposi’s sarcoma cell growth, invasion and angiogenesis 
[39–43].
Patients in this study presented with extensive and 
disseminated disease with 75.4 % having poor \ progno-
sis stage, a much higher proportion than reported from 
resource rich countries [44, 45]. Other reports from poor 
resource countries revealed that poor prognosis disease 
constitute 60–82 % of cases [14, 20, 36]. Majority of the 
patients with AIDS-related Kaposi’s sarcoma in this study 
presented with the disseminated form of the disease 
and most of them also had mixed lesions. AIDS-related 
Kaposi’s sarcoma usually follows an aggressive and fulmi-
nant course with involvement of multiple sites [20, 45]. 
In the present study female patients presented with more 
advanced AIDS-related Kaposi’s sarcoma, a finding that 
had been reported previously [20, 29, 46]. In addition, 
they had more aggressive disease which progressed rap-
idly. The reason why AIDS- related Kaposi’s sarcoma is 
more severe and progressed faster in females is not clear 
but does not seem to be related to immunologic differ-
ences since there was no significant difference between 
CD4 cells counts in males and females.
The lower limbs were most frequently affected with an 
associated lymphoedema which may be extensive and 
disproportionate to the extent of cutaneous disease. This 
lymphoedema may result from tumor involvement of 
dermal lymphatics or from the production by KS cells of 
growth factors that increase vascular permeability [46]. 
Additionally, HHV-8-induced exuberant proliferation of 
endothelial cells may lead to the occlusion of lymphatic 
vascular lumens leading to lymphoedema [46]. Why 
Kaposi’s sarcoma is common on the lower limbs is not 
clearly understood.
Involvement of the gastrointestinal tract (GIT) was 
seen in only 3.1 % of our patients. However, most patients 
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with GIT Kaposi’s sarcoma are asymptomatic, and 
because the lesions are submucosal they are not visual-
ized on contrast-enhanced radiographs [47]. Previous 
studies showed that asymptomatic GIT lesions have little 
clinical consequences hence; endoscopy should be car-
ried out only on symptomatic patients [27, 47]. However, 
in this study, the number of GI lesions may be underesti-
mated due to poor accessibility and affordability to endo-
scopic facilities.
In the present study, lymph node involvement by AIDS-
related Kaposi’s sarcoma commonly occurred in adults 
whereas; in patients without AIDS-related Kaposi’s sar-
coma lymph node involvement was exclusively a disease 
of children. This is in agreement with other researchers 
who reported similar observation [37, 48]. The fact that 
lymph node involvement by AIDS-related Kaposi’s sar-
coma was seen in adults is contrary to earlier reports 
that lymph node involvement by Kaposi’s sarcoma is 
exclusively a disease of children [48]. This suggests that 
AIDS-associated KS presents atypically with lymph node, 
gastrointestinal tract disease and other organ involve-
ment. Therefore the finding of atypical Kaposi’s sarcoma 
-lesions should arouse the suspicion of HIV infection.
As previously reported in other studies [49, 50], anae-
mia was a common presentation in patients with AIDS 
associated Kaposi’s sarcoma in this study. The causes of 
anaemia in AIDS-related Kaposi’s sarcoma are numer-
ous, and may include viral infections, chronic diseases, 
abnormal alterations in the level of cytokines, drug thera-
pies, opportunistic infections, and tumors infiltrating 
the bone marrow. Data from the Spectrum of Disease 
Study have indicated that correction of anaemia is asso-
ciated with prolongation of survival in AIDS [51]. Thus 
efforts should be made to establish the cause of anaemia 
in AIDS-related KS and appropriate treatment instituted.
Several modalities of treatment have been used for 
Kaposi’s sarcoma including chemotherapy, radiation ther-
apy, surgical excision and Highly Active Anti-Retroviral 
Therapy (HAART) in patients with AIDS-related Kaposi’s 
sarcoma [45]. The choice of treatment is determined by 
the stage of Kaposi’s sarcoma, its rate of progression, the 
degree of immune competence and HIV associated dis-
eases [52]. The selection of therapy for Kaposi’s sarcoma 
must take into account the potential benefit and adverse 
effects of treatment, interactions with other medications, 
and potential impact on underlying immunosuppression 
[52]. A wide variety of chemotherapeutic agents, indi-
vidually and in combination, have been evaluated for the 
treatment of Kaposi’s sarcoma. In high income countries, 
combination of vincristine, doxorubicin and bleomycin 
(VAB) that was considered the standard chemotherapy 
regimen for Kaposi’s sarcoma has been supplanted by 
liposomal anthracyclines due to their higher efficacy 
and reduced toxicity [44]. In addition, the angiogenic 
nature of Kaposi’s sarcoma makes it particularly suitable 
for therapies based on targeted agents such as metallo-
proteinase inhibitors, angiogenesis inhibitors and tyros-
ine kinase inhibitors [53]. In low income countries, the 
choice of therapeutic agents is limited to the combina-
tion of VAB or even more toxic drugs such as thalido-
mide because liposomal anthracyclines are not available 
or affordable [54]. In the present study, our patients were 
treated with a combination of vincristine, doxorubicin 
and bleomycin, similar to reports from other low income 
countries [54]. The internationally recommended chemo-
therapeutic agents such as Paclitaxel, Liposomal doxo-
rubicin and immune modulators (alpha interferon) were 
not used in this study due to high cost and unavailability. 
However, in terms of cost effectiveness, the VAB regi-
men is the most rational treatment option for Kaposi’s 
sarcoma patients in poor resource settings [53, 54]. It 
has been reported that six cycles of this regimen could 
produce a significant and quick response in sympto-
matic patients with advanced KS and produce an over-
all response rate of 50–88 % [36, 54]. In our study, only 
53.4 % of patients had significant improvement in qual-
ity of life at the end of the follow up period. This may be 
attributed to by the fact that more than a half of patients 
did not complete their treatment cycles because of death 
in the course of treatment after two to five courses, treat-
ment stopped because of severe side effects or were lost 
to follow up shortly after commencement of treatment.
When dealing with localized bulky or cosmetically dis-
turbing lesions, radiotherapy is the most effective local 
therapy. In this as in other reports, irradiated lesions 
regress with treatment, but recurrence, after 6  months 
is common [55]. In addition to providing effective pallia-
tion, radiotherapy is associated with minimal side effects. 
However, in our study, only 5 (2.0  %) of patients who 
required radiotherapy had access to this form of treat-
ment. This concurs with other studies in resource-limited 
countries [20, 26]. Failure to access this modality of treat-
ment in our patients can be explained by the fact that 
radiotherapy is not available in our center and therefore 
patients requiring this form of treatment had to travel 
long distances to receive radiotherapy at the oncological 
center. This sad observation calls for urgent establish-
ment of radiotherapy services in our center.
Although surgery is effective in excision of local-
ized isolated lesions, heroic surgery in the treatment of 
Kaposi’s sarcoma is unjustified and it is performed only 
in selected cases [20, 26]. In the present study, excision 
of ulcerated lesion and limb amputation were performed 
in four (1.6 %) patients each respectively. Similar surgical 
treatment pattern was performed by Ahmed and Muktar 
[29] in Nigeria.
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Previous studies have shown that patients with AIDS-
related Kaposi’s sarcoma are treated with a combina-
tion of chemotherapy and Highly Active Anti-Retroviral 
Therapy (HAART) with good results [29, 52, 54]. The 
effects of HAART on Kaposi’s sarcoma are multifacto-
rial and include inhibition of HIV replication, diminished 
production of HIV-1 transactivating protein Tat, recon-
stitution of immune response against HHV-8 and possi-
bly direct antiangiogenic activity by inclusion of protease 
inhibitors [56]. In the present study, decision to initiate 
systemic chemotherapy was based on the extent of Kapo-
si’s sarcoma in addition to other considerations such as 
patient KPS, end organ function, degree of immunosup-
pression, and other HIV co-morbidities. In patients with 
low tumor burden and slowly progressing disease, histo-
logical regression of existing KS lesions has been shown 
in response to HAART alone [56]. However, HAART 
alone cannot effectively control all cases of KS and there 
may be initial tumor progression as part of the immune 
reconstitution syndrome. In addition, it is not possible 
to state with certainty what proportion of patients with 
AIDS-related Kaposi’s sarcoma will benefit from HAART 
alone, or what are the precise characteristics that can be 
used to identify such patients. In low income countries 
like ours, chemotherapy consisting of a combination of 
vincristine, doxorubicin and bleomycin should be given 
simultaneously with HAART to patients that can physi-
ologically withstand such therapy [55, 56]. The toxicities 
observed following chemotherapy in our patients are 
similar to those reported in other studies using same reg-
imen and are well tolerated [57].
Palliative care for Kaposi’s sarcoma patients who are 
well tolerated may include adequate pain relief, reduction 
of the size of tumors with radiotherapy and reduction of 
the offensive smell of ulcerated lesions with appropri-
ate dressing argent. Prevention and treatment of other 
opportunistic infections is necessary as uncontrolled 
infections may stimulate Kaposi’s sarcoma progression 
probably due to production of angiogenic cytokines [29]. 
In our series, nine (3/8 %) of patients had only supportive 
care because of poor Karnofsky performance score and 
this included adequate pain relief by analgesics, reduc-
tion of offensive smell of ulcerated lesions with appro-
priate dressing argent and adequate treatment of other 
opportunistic infections.
One year mortality at our facility was 24.2  % among 
the-KS patients. This figure is high compared to 22.9  % 
that was reported by Ahmed and Muktar [29] in Nigeria. 
This high rate may be due not only to the fact that most 
of our patients presented with advanced HIV disease 
but also to the unavailability of chemotherapy and radi-
otherapy. In this study, poor ACTG stage, CD4+ count 
<200 cells/µl, associated co-morbid illness, disseminated 
disease and poor adherent to chemotherapy were the sig-
nificant independent factors associated with mortality in 
multivariate logistic regression analysis.
The follow-up of patients in this study was generally 
poor, and data on long-term survival were not avail-
able. This observation concurs with Asuquo et al. [37] in 
Nigeria. Poor follow-up of patients in our study may be 
explained by the fact that the majority of patients were 
lost to follow-up at the end of follow up period. In this 
study, the facility for measuring the viral load and dif-
ferences in viral genome was not available in our centre; 
this could have explained the differences in response to 
chemotherapy in the HIV subset. Radiation therapy pro-
vides excellent results with few side effects in all types 
of Kaposi’s sarcoma. However, only a few of our patients 
had radiotherapy, as this facility is not available in our 
centre. Those referred for radiotherapy were unwilling 
because of cost and long distance. However, despite these 
challenges, the study has provided local data that can 
help healthcare providers in the management of patients 
with Kaposi’s sarcoma. The challenges identified in the 
management of Kaposi’s sarcoma in our setting need to 
be addressed in order to deliver optimal care for these 
patients.
Conclusion
Kaposi’s sarcoma remains a common malignant vascular 
tumor in this region and is commonly associated with 
HIV/AIDS. The patients present late with extensive and 
advanced disease that requires systemic treatment. Late 
presentation, Lack of awareness of the disease, poor 
accessibility to healthcare facilities, poor diagnostic and 
treatment resources, irregular availability of chemother-
apy and HAART, the high cost of care, loss to follow up 
and lack of radiotherapy services at our centre are among 
the hallmarks of the disease in this region and pose a 
great challenge in the management of these patients. 
Therefore public enlightenment, early diagnosis, and 
effective cost-effective treatment and follow-up will help 
reverse this trend.
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